Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

• Status: Not yet recruiting
• Trial end date: 2027-05-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tharick Pascoal
• Collaborator: National Institute on Aging (NIA)
• Treatments: Radiopharmaceuticals

Criteria

Inclusion criteria:

• Have an informant who will be able to provide an independent evaluation of functioning.

• Willing and capable of undergoing repeated MR/PET imaging.

• Fluent in a language approved by the coordinating center.

• At screening, must have no cognitive impairment, or meet criteria for single- or multiple-domain amnestic mild cognitive impairment or Alzheimer's disease dementia.

Exclusion criteria:

• Inability to provide informed consent by self or by proxy.

• Pregnant or breastfeeding women.

• Have any condition or are taking any medication that could increase the risk to the participant, limit the ability to tolerate or interfere with the results of the tests and procedures (in the opinion of the investigator).